Lucitanib Clinical Development Overview

Lucitanib, is an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRα/β) and fibroblast growth factor receptors 1 through 3 (FGFR 1-3). The LIO-1 Phase 2 study, evaluating lucitanib and nivolumab in gynecologic cancers has completed enrollment. 

Clovis has global rights for lucitanib excluding China.

Lucitanib Scientific Presentations

Efficacy and Safety of Lucitanib + Nivolumab in Patients With Advanced Gynecologic Malignancies: Phase 2 Results From the LIO-1 Study (NCT04042116; ENGOT-GYN3/AGO/LIO)

Poster Presentation 2022 ASCO Annual Meeting

LIO-1: Initial Phase 2 Experience of Lucitanib + Nivolumab in Patients With Metastatic or Recurrent Cervical Cancer (NCT04042116; ENGOT-GYN3/AGO/LIO)

Oral Presentation 2022 SGO Annual Meeting